Patient data
| Patient no | Age (years) | Gender | Duration of symptoms (days) | Maximal diameter of SMH (disc diameter) | BCVA preop | BCVA 4 weeks postop | BCVA 12 weeks postop | Displacement of SMH | Anticoagulation | Lens status preop | Lens status postop | Complications |
| 1 | 77 | M | 3 | 1.5 | 0.7 | 0.3 | 0.3 | Complete | None | Phakic | Pseudophakic | None |
| 2 | 82 | F | 7 | 2.5 | 1.6 | 0.5 | 0.3 | Complete | None | Phakic | Pseudophakic | None |
| 3 | 85 | M | 6 | 4 | 3.0 | 0.8 | 0.2 | Complete | Clopidogrel | Phakic | Pseudophakic | None |
| 4 | 86 | F | 8 | 1.75 | 1.6 | 1.0 | 1.3 | Complete | Aspirin | Phakic | Pseudophakic | None |
| 5 | 84 | F | 2 | 1.75 | 0.7 | 0.9 | 1.0 | Complete | None | Pseudophakic | Pseudophakic | Retinal pigment epithelium-rip |
| 6 | 86 | F | 14 | 4 | 1.6 | 1.3 | 0.8 | Complete | None | Pseudophakic | Pseudophakic | None |
| 7 | 90 | F | 2 | 8.5 | 3.0 | 3.0 | 1.6 | Incomplete | None | Pseudophakic | Pseudophakic | SMH recurrence, vitreous haemorrhage 3 weeks postop |
| 8 | 74 | M | 7 | 9 | 3.0 | 0.7 | 1.0 | Complete | Dipyridamole+aspirin | Phakic | Pseudophakic | SMH recurrence 5 weeks postop |
| 9 | 71 | F | 1 | NA | 3.0 | 1.6 | 1.6 | Incomplete | Aspirin | Phakic | Phakic | None |
| 10 | 79 | F | 1 | 2 | 1.3 | 1.3 | 1.0 | Incomplete | None | Pseudophakic | Pseudophakic | Secondary macular hole |
| 11 | 82 | F | 5 | 2.75 | 1.6 | 1.6 | 0.5 | Complete | Aspirin | Pseudophakic | Pseudophakic | None |
| 12 | 82 | F | 2 | 10 | 1.3 | 1.0 | 1.3 | Complete | Aspirin | Pseudophakic | Pseudophakic | None |
Patient 9 presented with vitreous haemorrhage.
Aspirin, aspirin 100 mg per os once daily; BCVA, best-corrected Snellen visual acuity (logMAR), logMAR 3.0 is equal to hand motion at 60 cm; CNV, choroidal neovascularisation; disc, disc diameter; F, female; M, male; SMH, submacular haemorrhage.